



Press Release

FOR IMMEDIATE RELEASE

Acquisition of Cilian by Bioceros accompanied by a restructuring of executive and supervisory board of Cilian AG

Münster, Germany, September 7th, 2005 – Bioceros, a privately held biopharmaceutical research and development contract organization, announced the acquisition of Cilian AG, a privately held company leveraging a novel expression system to produce recombinant proteins and therapeutic enzymes at an unmatched quality and price.

“The acquisition of Cilian by Bioceros will strengthen our intellectual proprietary and service portfolio. The combined entity will benefit from each others experience, expertise and know-how to become a successful hybrid biotechnology company with both service for fee activities and proprietary research and development,” said Remco Brandt, managing director of Bioceros BV.

“For Cilian AG the merger with Bioceros opens up opportunities for early revenues, which allows our R&D team to develop the proprietary Ciliate based expression technology while being close to the market and consequently to focus on the market entry,” said Marcus Hartmann, CSO of Cilian AG.

In connection with the acquisition, executive and supervisory board of Cilian AG has been restructured reflecting the new corporate structure as well as the implementation of a service strategy. Remco Brandt, the managing director of Bioceros BV, will succeed Christine Lemke as CEO.

Mark de Boer, chairman of the supervisory board of Bioceros BV, said: “I would like to thank Christine Lemke, Theodor Dingermann, Oscar Goddijn and Sander Slootweg for their dedication and professional contributions to Cilian AG. The members of the supervisory board and



Lemke as CEO have played a pivotal role in transitioning the business model from a platform technology towards products and services. Their advice, experience and visionary strengths have been invaluable to the Company and have strongly supported a successful establishment of Cilian AG.”

About Bioceros

Bioceros, founded in April 2003, is a privately held biopharmaceutical contract organization providing a broad spectrum of technical and scientific expertise ranging from discovery research to pre-clinical development. In its well-equipped laboratory an experienced team performs (i) cell-based immunoassays, which can be used for screening of new drug leads influencing the immune system, (ii) molecular biology R&D as well as (iii) pre-clinical studies. Additionally Bioceros' consultancy services add value to biopharmaceutical companies and academic institutions by optimizing research programs and valorization of their research.

About Cilian AG

Founded in 2001 by Marcus Hartmann and partners, Cilian is an emerging biotechnology company developing and marketing a novel expression system. The Company uses a species of Ciliates, a eukaryotic single-cell organism, for the production of enzymes and therapeutic proteins. While Ciliates secrete a number of therapeutically relevant enzymes with high expression rates by nature, recombinant proteins are produced by Ciliates using genetically modified cells. Leveraging the unique capabilities of the Ciliates, the Company aims to produce proteins at an unmatched quality and price, thereby fulfilling its mission to improve human health by facilitating access to biopharmaceuticals.

For more information:

Bioceros BV:

www.bioceros.com

Remco M. Brandt, M.Sc.

tel. +31 (0) 30-253 7910

Cilian AG:

www.cilian.de

Marcus Hartmann, Ph.D. (CSO)

tel. +49 (0) 251 6 20 310